EGFR Archives
VUMC adopts updated kidney function equation to better guide patient care decisions
Nov. 17, 2022—In December Vanderbilt University Medical Center will again update the equation used for estimating kidney function with the goals of improving health equity and better guiding patient care decisions.
Study supports removing race from estimate of kidney function
Nov. 17, 2022—An in-depth analysis by Vanderbilt investigators of published research studies supports removing race from the calculation of estimated glomerular filtration rate (eGFR) — an assessment of kidney function.
Inflammatory driver of obesity
Aug. 25, 2022—Blocking the EGF receptor signaling pathway in immune system macrophages represents a new target for improving insulin resistance in people with obesity.
Study reveals need for matching targeted therapies with EGFR subtypes
Jul. 28, 2022—A Vanderbilt study suggests that clinicians should take a deeper dive into distinguishing EGFR mutations when prescribing targeted therapies for non-small-cell lung cancers.
New prognosis predictor and target for gastric cancer
Apr. 7, 2022—The protein CGA — a subunit of glycoprotein hormones — is a biomarker that predicts chemoresistance in gastric cancer and could be targeted along with EGFR to restore chemosensitivity.
The role of polarity in early cancer
Sep. 21, 2021—Mutations in the protein epiregulin, an EGF receptor ligand, affect larger epithelial cell reorganization and may contribute to early cancer development, Vanderbilt researchers discovered.
Blocking tumor ‘signals’ and ‘fuel’
Aug. 25, 2020—Combining two drugs reduced colorectal cancer cell growth in vitro and in an animal model, suggesting the combination may be a promising treatment for patients.
Protein study may be key to treating fibrotic diseases
Jul. 30, 2020—A protein linked to amyotrophic lateral sclerosis (ALS), a progressive neurological disease that causes muscle weakness, may be a key to treating fibrotic disease of the kidneys and other organs, researchers at Vanderbilt University Medical Center reported recently.
Group’s efforts lead to removal of race as a variable in common test of kidney function
Jul. 13, 2020—A group of Vanderbilt students, residents and faculty — connected through their passion for health equity — have identified and worked together to rectify longstanding concerns about the inappropriate use of race as a variable in the calculation of estimated glomerular filtration rate (eGFR), which estimates a patient’s level of kidney function and helps determine the stage of kidney disease.
Sex differences in kidney injury
Jul. 25, 2019—Men are more susceptible to progressive kidney disease than women; new VUMC studies point to differences in the expression and activation of the EGF receptor.
Targeting diabetic kidney disease
Oct. 12, 2018—Pathways activated by the epidermal growth factor receptor may be attractive targets to treat diabetic kidney disease, according to new findings from Vanderbilt investigators.
YAP after acute kidney injury
Aug. 16, 2018—Activation of the signaling protein YAP may be a target for treating acute kidney injury, which affects up to 20 percent of hospitalized patients.
